Drug Trial Radar · NCT00616928
Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years
Last checked: Nov 20, 2026Latest source record: Jun 8, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,561
Actual
Start
Jan 23, 2008
Primary completion
Oct 15, 2008
Study completion Mar 19, 2009
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Feb 15, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this Phase 3, observer-blind, placebo-controlled, multi-center study is to characterize the immunogenicity \& safety of the investigation vaccination regimen of GSK 1557484A vaccine given to adults aged ≥18 years.
Conditions
- Influenza
Interventions
Influenza A (H5N1) Virus Monovalent Vaccine, AdjuvantedBiological
Two intramuscular injections at Days 0 and 21.
PlaceboBiological
Two intramuscular injections at Days 0 and 21.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Seroconverted Subjects Against A/Indonesia/5/2005 (H5N1)Time frame: At Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)
- Number of Seroprotected Subjects Against A/Indonesia/5/2005 (H5N1)Time frame: At Day 0 and Day 42 post Dose 1 (Day 42 post Dose 1 = Day 21 post Dose 2)
- Number of Subjects With Any Solicited Local Symptoms.Time frame: During a 7-day follow-up period (i.e., day of vaccination and 6 subsequent days) after each vaccine administration
- Number of Subjects With Any Solicited General Symptoms.Time frame: During a 7-day follow-up period (i.e., day of vaccination and 6 subsequent days) after each vaccine administration
- Number of Subjects With Any Unsolicited Adverse Events (AEs).Time frame: During a 21-day follow-up period for each vaccine administration, as well as overall (Day 0 through Day 84)
- Number of Subjects With Serious Adverse Events (SAEs)Time frame: From Day 0 through Day 182 and through Day 379.
- Number of Subjects With Medically Attended Events (MAEs)Time frame: From Day 0 through Day 182 and through Day 364.
Locations
40 sites in 2 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Huntsville, Alabama
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Anaheim, California
GSK Investigational Site
Jacksonville, Florida
GSK Investigational Site
Melbourne, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Pembroke Pines, Florida
GSK Investigational Site
Stockbridge, Georgia
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
Peoria, Illinois
GSK Investigational Site
South Bend, Indiana
GSK Investigational Site
Lenexa, Kansas
GSK Investigational Site
Wichita, Kansas
GSK Investigational Site
Metairie, Louisiana
GSK Investigational Site
Rockville, Maryland
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Missoula, Montana
GSK Investigational Site
Las Vegas, Nevada
GSK Investigational Site
Edison, New Jersey
GSK Investigational Site
Poughkeepsie, New York
GSK Investigational Site
Rochester, New York
GSK Investigational Site
Raleigh, North Carolina
GSK Investigational Site
Cleveland, Ohio
GSK Investigational Site
Erie, Pennsylvania
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Spartanburg, South Carolina
GSK Investigational Site
Nashville, Tennessee
GSK Investigational Site
Austin, Texas
GSK Investigational Site
Fort Worth, Texas
GSK Investigational Site
San Angelo, Texas
GSK Investigational Site
Halifax, Nova Scotia, Canada
GSK Investigational Site
Truro, Nova Scotia, Canada
GSK Investigational Site
Greater Sudbury, Ontario, Canada
GSK Investigational Site
London, Ontario, Canada
GSK Investigational Site
Sarnia, Ontario, Canada
GSK Investigational Site
Woodstock, Ontario, Canada
GSK Investigational Site
Pointe-Claire, Quebec, Canada
GSK Investigational Site
Québec, Quebec, Canada
GSK Investigational Site
Saint Romuald, Quebec, Canada
GSK Investigational Site
Sherbrooke, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.